HSD3B1 and Familial prostate cancer: The relative simplicity of obtaining germline DNA combined with an established mechanism through which HSD3B1 inheritance confers resistance to castration using an extragonadal androgen-dependent mechanism strongly supports integration of HSD3B1 into prostate cancer clinical trials in development, and thus the potential role of HSD3B1 in routine clinical care remains to be determined.